Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 A resurrection of aducanumab for Alzheimer's disease.

Literature DB >> 31978357

A resurrection of aducanumab for Alzheimer's disease.

Lon Schneider.

Abstract

Entities: Disease

Year: 2019 PMID： 31978357 DOI： 10.1016/S1474-4422(19)30480-6

Source DB: PubMed Journal: Lancet Neurol ISSN： 1474-4422 Impact factor: 44.182

Keyword Cloud
Cited

× No keyword cloud information.

59 in total

1. Evidence for aggregation-independent, PrP^C-mediated Aβ cellular internalization.

Authors: Alejandro R Foley; Graham P Roseman; Ka Chan; Amanda Smart; Thomas S Finn; Kevin Yang; R Scott Lokey; Glenn L Millhauser; Jevgenij A Raskatov
Journal: Proc Natl Acad Sci U S A Date: 2020-11-02 Impact factor: 11.205

Review 2. Radioactive synthesis of tau PET imaging agent ¹⁸F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Authors: Wenyan Zhang; Shuoyan Xu; Hongmei Yu; Xuena Li; Zhuangzhuang Jin; Yaming Li; Zhiyi He
Journal: Ann Nucl Med Date: 2021-01-18 Impact factor: 2.668

Review 3. Can we learn lessons from the FDA's approval of aducanumab?

Authors: Kathy Y Liu; Robert Howard
Journal: Nat Rev Neurol Date: 2021-09-17 Impact factor: 42.937

Review 4. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

Authors: Tiantian Guo; Denghong Zhang; Yuzhe Zeng; Timothy Y Huang; Huaxi Xu; Yingjun Zhao
Journal: Mol Neurodegener Date: 2020-07-16 Impact factor: 14.195

5. 14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease.

Authors: Wenjun Chen; Mengyao Wang; Minzhen Zhu; Wenchao Xiong; Xihe Qin; Xinhong Zhu
Journal: J Neurosci Date: 2020-09-24 Impact factor: 6.167

Review 6. Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.

Authors: Sara Cunha; Ben Forbes; José Manuel Sousa Lobo; Ana Catarina Silva
Journal: Int J Nanomedicine Date: 2021-06-29

A resurrection of aducanumab for Alzheimer's disease.

1. Evidence for aggregation-independent, PrP^C-mediated Aβ cellular internalization.

Review 2. Radioactive synthesis of tau PET imaging agent ¹⁸F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Review 3. Can we learn lessons from the FDA's approval of aducanumab?

Review 4. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

5. 14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease.

Review 6. Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.

Review 7. Metabolic disorder in Alzheimer's disease.

Review 8. The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer's Disease.

9. The Blood-Brain Barrier in Alzheimer's Disease.

Review 10. Iron and Ferroptosis as Therapeutic Targets in Alzheimer's Disease.

A resurrection of aducanumab for Alzheimer's disease.

1. Evidence for aggregation-independent, PrPC-mediated Aβ cellular internalization.

Review 2. Radioactive synthesis of tau PET imaging agent 18F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.

Review 3. Can we learn lessons from the FDA's approval of aducanumab?

Review 4. Molecular and cellular mechanisms underlying the pathogenesis of Alzheimer's disease.

5. 14,15-Epoxyeicosatrienoic Acid Alleviates Pathology in a Mouse Model of Alzheimer's Disease.

Review 6. Improving Drug Delivery for Alzheimer's Disease Through Nose-to-Brain Delivery Using Nanoemulsions, Nanostructured Lipid Carriers (NLC) and in situ Hydrogels.

Review 7. Metabolic disorder in Alzheimer's disease.

Review 8. The Protective A673T Mutation of Amyloid Precursor Protein (APP) in Alzheimer's Disease.

9. The Blood-Brain Barrier in Alzheimer's Disease.

Review 10. Iron and Ferroptosis as Therapeutic Targets in Alzheimer's Disease.

1. Evidence for aggregation-independent, PrP^C-mediated Aβ cellular internalization.

Review 2. Radioactive synthesis of tau PET imaging agent ¹⁸F-AV-1451 and its role in monitoring the progression of Alzheimer's disease and supporting differential diagnosis.